BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:45-56. [DOI: 10.14309/ajg.0000000000000844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Khan N, Patel D, Pernes T, Patel M, Trivedi C, Medvedeva E, Xie D, Yang Y. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2021;3:otab022. [DOI: 10.1093/crocol/otab022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yuan S, Wang Q, Li J, Xue JC, Li Y, Meng H, Hou XT, Nan JX, Zhang QG. Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment. Chin Med 2022;17:74. [PMID: 35717380 DOI: 10.1186/s13020-022-00633-4] [Reference Citation Analysis]
3 Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac048. [PMID: 35353189 DOI: 10.1093/ibd/izac048] [Reference Citation Analysis]